Severe pulmonary, cardiac or other systemic disease, specifically:

Cardiac or pulmonary disorders within  months of enrollment.

Participants who have undergone a pneumonectomy due to known potential for pulmonary toxicities and heightened risk for complications

Pulmonary hypertension

The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study.

Other cardiac or pulmonary disease that, at the investigators discretion, can impair treatment safety

Significant pulmonary disease or condition

Severe pulmonary hypertension (PHT) (on echo or right side cardiac catheterization);

Significant pulmonary disease, including pulmonary hypertension or interstitial pneumonitis

Significant pulmonary disease or condition

Severe pulmonary disease (despite above oxygen saturation and DLCO) including severe and uncontrolled asthma (per  National Heart, Lung, and Blood Institute [NHLBI] Guidelines for the Diagnosis and Treatment of Asthma Expert Panel Report ), chronic obstructive pulmonary disease, and/or pulmonary hypertension (PH); a diagnosis of PH will be made by finding of mean pulmonary artery pressure (mPAP) <  mm Hg on right heart catherization; in patients unable and/or unwilling to undergo cardiac catheterization, patients will be excluded with the following constellation of findings based upon presumptive diagnosis of PH (positive predictive value [PPV] of %): TRJ velocity > . m/sec AND either N-terminal pro-brain natriuretic peptide (NT-pro-BNP) >=  pg/ml OR -minute walk distance <  m

Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli

Severe pulmonary hypertension (PHT) (on echo or right side cardiac catheterization)

Uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension, idiopathic pulmonary fibrosis) that in the opinion of the investigator would put the participant at significant risk for pulmonary complications during the study

Significant pulmonary artery hypertension (PAH) defined as:\r\n* Peak systolic pulmonary artery pressure >  mmHg by resting echocardiogram will require right heart catheterization; if pulmonary artery pressure (PAP) is not evaluable on echocardiogram due to lack of a Tricuspid regurgitant jet, then normal anatomy and function as evidenced by normal right atrium and ventricle size, shape and wall thickness and septum shape must be documented to rule-out PAH; otherwise, right heart catheterization is indicated; prior history of PAH but controlled with medications will not exclude patients from the protocol; PAH is considered controlled with medications if peak systolic pulmonary artery pressure is <  mmHg or mean pulmonary artery pressure by right heart catheterization is <  mmHg at rest\r\n* Mean pulmonary artery pressure by right heart catheterization exceeding  mmHg at rest; if mean PAP is elevated and pulmonary vascular resistance and transpulmonary gradient are normal then the patient is eligible for the protocol\r\n* New York Heart Association (NYHA)/World Health Organization Class III or IV

Pulmonary hypertension.

Anuria, dehydration, severe pulmonary congestion or pulmonary edema or fixed low cardiac input

Treated with appropriate maximal medical therapy for pulmonary toxicity

use of systemic steroids or immunosuppressive medication Pulmonary hypertension will not be an exclusion criterion as patients with pulmonary hypertension were shown to have higher bursting pressures following PA sealing in previous studies.

EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with an FEV of =< % or DLCO (corrected) < % will be excluded

EXCLUSION CRITERIA FOR TNBC: Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with an FEV of =< % or DLCO (corrected) < % will be excluded

Patient has severe pulmonary, cardiac, or other systemic disease, specifically:

No cardiomegaly or bilateral pulmonary infiltrates on chest radiograph; patients may have pulmonary metastatic lesions

ELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: No cardiomegaly or bilateral pulmonary infiltrates on chest radiograph; patients may have pulmonary metastatic lesions

Subjects with a history of pulmonary hypertension is excluded

No overt cardiac, gastrointestinal, pulmonary or psychiatric disease

Patients with renal, hepatic, pulmonary, or cardiac disease that exclude delivery of standard chemotherapy

known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function

Clinically no evidence of pulmonary disease

Evidence of pulmonary insufficiency

Other cardiac or pulmonary disease that, at the investigators discretion, can impair treatment safety

Patients must have no overt cardiac, gastrointestinal, pulmonary or psychiatric disease

Chronic pulmonary aspergillosis, pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis (ABPA).

Symptomatic pulmonary KS

No overt renal, hepatic, cardiac or pulmonary disease

Clinical evidence of pulmonary insufficiency

Patients with radiographic changes including pulmonary disease, including but not limited to: pulmonary nodules, infiltrates, pleural effusion are excluded unless cleared by pulmonary biopsy showing no evidence for pulmonary infection

No overt cardiac, gastrointestinal, pulmonary or psychiatric disease

Significant pulmonary disease or condition

History of pulmonary disease or abnormal pulmonary function studies

DLCO ? % predicted with no symptomatic pulmonary disease. If DLCO is ?% and < % and the patient is asymptomatic, a pulmonary consult is required

Pulmonary metastases

Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD], pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study

Pulmonary nodules >  mm\r\n* Pulmonary nodules >  mm that have been stable for >  months and are not clearly metastatic disease per the treating investigator are permitted

Significant pulmonary disease, including pulmonary hypertension or interstitial pneumonitis

History of pulmonary hypertension

Pulmonary hypertension

History of documented pulmonary embolus within  months of enrollment

No overt renal, hepatic, cardiac or pulmonary disease

The patient has uncontrolled, clinically significant pulmonary disease (e.g., COPD, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.

Pulmonary LCNEC;

Stable cardiovascular, pulmonary health status

Pulmonary hypertension.

Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.

Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.

Significant pulmonary disease, including pulmonary hypertension or interstitial pneumonitis

Known history of pulmonary hypertension

Anuria, dehydration, severe pulmonary congestion or pulmonary edema or fixed low cardiac input since all are conditions for which osmotic diuresis are contraindicated and ascorbic acid has high osmolarity

Pulmonary disease including or greater than grade  dyspnea or laryngeal edema, grade  pulmonary edema or pulmonary hypertension according to CTCAE .

Moderate or severe pulmonary hypertension defined as pulmonary arterial systolic pressure (PASP) >  mm Hg

Pulmonary hypertension

Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen

Patients with known pulmonary hypertension

Patients with severe pulmonary hypertension \r\n* Tricuspid jet velocity > . m/sec

Moderate or severe pulmonary hypertension defined as pulmonary artery systolic pressure (PASP) > mm Hg; for those patients where PASP is indeterminate, moderate to severe symptoms of pulmonary hypertension (World Health Organization functional assessment class III or IV) will be used to determine exclusion criteria

> unilateral pulmonary metastasis

Patients with compromised pulmonary disease.

DONOR: Significant pulmonary disease

Pulmonary:

Ineligible for curative pulmonary metastasectomy

Grade  or greater edema (eg, peripheral, pulmonary)

Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen

Any history or signs of pulmonary lymphangitic spread;

Known pulmonary hypertension of any severity.

Significant pulmonary compromise

Clinical Pulmonary Infection Score (CPIS) of at least 

History of symptomatic pulmonary disease or non-malignant pulmonary disease requiring treatment.

The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.

Pulmonary: new onset hypoxia

Echocardiographic evidence of pulmonary hypertension.

Pulmonary hypertension,

No symptomatic cardiac or pulmonary disease and a performance status equal to or =< 

Known pulmonary hypertension

Uncontrolled cardiac or pulmonary disease

Acute pulmonary embolus or pulmonary infarction in the last week

Diagnosis of pulmonary hypertension

Diagnosis of pulmonary hypertension

Patients with pulmonary edema, congestive heart failure or pulmonary embolus

severe pulmonary hypertension

Severe pulmonary hypertension

Participant has ever experienced one or more hepatic decompensation events or a history of decompensated liver disease as listed below:\r\n* Clinical ascites\r\n* Variceal bleeding documented by endoscopy\r\n* Spontaneous bacterial peritonitis documented by positive culture\r\n* Hepatic encephalopathy\r\n* Hepatorenal syndrome (type  or )\r\n* Porto-pulmonary hypertension\r\n* Hepato-pulmonary hypertension\r\n* Any liver-related event which led to a hospitalization or a grade  event

Evidence of severe pulmonary infections, as judged by the investigator

unstable pulmonary or cardiovascular conditions.

Patients with pulmonary hypertension or unstable cardiopulmonary conditions

Known pulmonary hypertension

Patients with pulmonary hypertension or unstable cardiopulmonary conditions

Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli

Suspected pulmonary hypertension: additional testing required, such as echocardiogram

Right to left shunt, severe pulmonary hypertension (pulmonary artery pressure >  mmHg), or adult respiratory distress syndrome

PATIENT: Patients with severe emphysema, pulmonary vasculitis, pulmonary hypertension or a history of pulmonary emboli

Right to left shunt, severe pulmonary hypertension (pulmonary artery pressure >  mmHg), or adult respiratory distress syndrome

Patients with severe emphysema, pulmonary vasculitis, pulmonary hypertension, respiratory distress syndrome, or a history of pulmonary embolism.

Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension or a history of pulmonary emboli

Severe emphysema, pulmonary emboli, or other conditions that cause pulmonary hypertension due to compromised pulmonary-arterial vasculature

Patients who have a known cardiac shunt or pulmonary hypertension

Patients with known pulmonary hypertension

Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli

Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli

With significant heart or pulmonary disease.